We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy.
- Authors
Wang, Chin-Chou; Chiu, Li-Chung; Tung, Pi-Hung; Kuo, Scott Chih-Hsi; Chu, Chia-Hsun; Huang, Allen Chung-Cheng; Wang, Chih-Liang; Chen, Chih-Hung; Yang, Cheng-Ta; Hsu, Ping-Chih
- Abstract
Introduction: The clinical features of patients with metastatic epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma receiving first-line therapy based on erlotinib combined with bevacizumab are unclear. Here, we sought to analyze the clinical features of this patient group. Methods: Data were analyzed for the period from January 2015 to August 2019 for 49 patients with metastatic EGFR-mutated lung adenocarcinoma receiving first-line erlotinib-and-bevacizumab combination therapy from the Linkou and Kaohsiung Chang Gung Memorial Hospitals. Results: The combination of erlotinib and bevacizumab showed an 83.7% objective response rate and a 97.9% disease control rate. The median progression-free survival (PFS) and overall survival (OS) were 22.0 [95% CI (19.7–22.33)] and 47.6 [95% CI (38.87–56.37)] months, respectively, for all patients. The secondary EGFR-T790M mutation rate in the patients with acquired resistance to the combination was 72.4%. No predictive factor associated with the appearance of secondary EGFR-T790M mutations was found. The most frequent adverse event (AE) caused by the combination therapy was dermatitis (100%), and most of the AEs were manageable and grades 1 and 2. Conclusion: Erlotinib combined with bevacizumab is an effective and safe therapy for untreated metastatic EGFR-mutated lung adenocarcinoma. The combination does not alter secondary EGFR-T790M mutations in patients with acquired resistance and is feasible in real-world clinical practice.
- Subjects
EPIDERMAL growth factor receptors; BEVACIZUMAB; LUNGS; ERLOTINIB; OVERALL survival; SURVIVAL rate; ADENOCARCINOMA
- Publication
Oncology & Therapy, 2021, Vol 9, Issue 2, p489
- ISSN
2366-1070
- Publication type
Article
- DOI
10.1007/s40487-021-00152-6